Investigation of the stress burden of psoriasis patients before and under a modern biologic treatment

Investigation of the stress burden of psoriasis patients before and under a modern biologic treatment - PSOSTRESS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023751

Enrollment

100

Registered

2020-12-11

Start date

2021-01-18

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L40.0

Interventions

Group 1: Patients suffering from moderate to severe psoriasis that are initiating systemic treatment will be asked for blood and salivary samples and to fill out several questionnaires before treatmen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Patients suffering from plaque psoriasis with an indication for systemic treatment (PASI > 10) • Control persons, not suffering from a chronic disease

Exclusion criteria

Exclusion criteria: - Pregnant or breast-feeding women - Insufficient communication skills in the German language, dementia or functional analphabetism - Lack of capacity or will to consent to the study - Existing contraindication to therapy with IL-17 or IL-23 inhibitors

Design outcomes

Primary

Measure	Time frame
• Comparison of cortisol and alpha amylase activity as assessed with salivary samples between psoriasis patients before the initiation of a biologic therapy (IL-23 or IL-17 inhibitors) and healthy controls • Comparison of cortisol and alpha amylase activity as assessed with psoriasis patients' salivary samples before the initiation of a biologic therapy (IL-23 or IL-17 inhibitors) and after 4 weeks • Comparison of psychological burden caused by symptoms of stress, depression and anxiety among psoriasis patients before the initiation of a biologic therapy (IL-23 or IL-17 inhibitors) with healthy controls • Comparison of psychological burden caused by symptoms of stress, depression and anxiety among psoriasis patients before the initiation of a biologic therapy (IL-23 or IL-17 inhibitors) and after 4 weeks	—

Measure

Time frame

• Comparison of cortisol and alpha amylase activity as assessed with salivary samples between psoriasis patients before the initiation of a biologic therapy (IL-23 or IL-17 inhibitors) and healthy controls • Comparison of cortisol and alpha amylase activity as assessed with psoriasis patients' salivary samples before the initiation of a biologic therapy (IL-23 or IL-17 inhibitors) and after 4 weeks • Comparison of psychological burden caused by symptoms of stress, depression and anxiety among psoriasis patients before the initiation of a biologic therapy (IL-23 or IL-17 inhibitors) with healthy controls • Comparison of psychological burden caused by symptoms of stress, depression and anxiety among psoriasis patients before the initiation of a biologic therapy (IL-23 or IL-17 inhibitors) and after 4 weeks

—

Secondary

Measure	Time frame
- Correlation of salivary cortisol and alpha amylase with psoriasis severity (assessed with the established Psoriasis area and severity Index (PASI)) - Correlation of salivary cortisol and alpha amylase with self-reported psychosocial stress, as well as depressive and anxious symptoms - Correlation of salivary cortisol and alpha amylase with blood serum pro-inflammatory cytokines	—

Countries

Germany

Contacts

Public ContactWiebke Sondermann

Universitätsklinikum Essen (AöR), Klinik für Dermatologie, Venerologie und Allergologie

wiebke.sondermann@uk-essen.de0201 723 3647

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026